EPS for Xenon Pharmaceuticals Inc. (XENE) Expected At $-0.47

October 13, 2018 - By Adrian Erickson

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Logo

Analysts expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to report $-0.47 EPS on November, 6.They anticipate $0.04 EPS change or 9.30 % from last quarter’s $-0.43 EPS. After having $-0.45 EPS previously, Xenon Pharmaceuticals Inc.’s analysts see 4.44 % EPS growth. The stock increased 3.05% or $0.31 during the last trading session, reaching $10.48. About 220,582 shares traded or 2.53% up from the average. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has risen 352.38% since October 14, 2017 and is uptrending. It has outperformed by 336.76% the S&P500.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company has market cap of $262.09 million. The firm uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It currently has negative earnings. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.